Lior Soussan‐Gutman

Atotech (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

20h-index2.9kcitations87works1.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(39), Lung Cancer Treatments and Mutations(31), Breast Cancer Treatment Studies(23), Advanced Breast Cancer Therapies(18), HER2/EGFR in Cancer Research(11)

Publications87 total

EP.06.73 Co-Driver Mutations in Fusion-Positive NSCLC: Liquid Biopsy Insights From 2,369 Patients
Journal of Thoracic Oncology·2025
ER + HER2- early-stage breast cancer: association of HER2 expression, tumor characteristics, and outcomes
Breast Cancer Research and Treatment·2024Open Access
P3.06D.09 Reciprocal DNA Fusions and their Association with DNA Damage Response Genes in Patients with NSCLC Through cfDNA NGS
Journal of Thoracic Oncology·2024Open Access
Treatments and clinical outcomes in stage II colon cancer patients with 12-gene Oncotype DX Colon Recurrence Score® assay-guided therapy: real-world data
ESMO Open·2024· 5 citedOpen Access
Abstract PO5-01-08: The impact of Human Epidermal growth factor Receptor 2 (HER2) expression by RT-PCR on tumor characteristics and outcome in estrogen receptor (ER) positive, HER2 negative early-stage breast cancer
Cancer Research·2024
BRCA1/2 mutation carriers vs the general breast cancer population (N = 799,986): 21-gene assay-based molecular characterization
Breast Cancer Research and Treatment·2024· 1 citedOpen Access
Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry
npj Breast Cancer·2023· 3 citedOpen Access
Clinical outcomes in estrogen receptor-positive early-stage breast cancer patients with Recurrence Score 26-30: observational real-world cohort study
npj Breast Cancer·2023· 4 citedOpen Access
Treatments and clinical outcomes in stage II colon cancer (CC) patients (pts) with 12-gene Oncotype DX Colon Recurrence Score assay-guided therapy: Real-world data.
Journal of Clinical Oncology·2023· 1 cited
Data from Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer
2023Open Access
Supplementary Tables 1 - 2, Figures 1 - 2 from Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer
2023Open Access
Supplementary Tables 1 - 2, Figures 1 - 2 from Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer
2023Open Access
Data from Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer
2023Open Access
Supplementary Patient Data from Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer
2023Open Access
Supplementary Patient Data from Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer
2023Open Access
Abstract P3-05-59: ER+ HER2-negative mBRCA1/2 carriers breast cancer patients (n=81): Clinical outcomes and molecular characterization via the 21-gene Breast Recurrence Score (RS) test vs the general RS-tested population (799,986 samples)
Cancer Research·2023· 1 cited
Liquid First Is “Solid” in Naïve Non-Small Cell Lung Cancer Patients: Faster Turnaround Time With High Concordance to Solid Next-Generation Sequencing
Frontiers in Oncology·2022· 9 citedOpen Access
Recurrence Score (RS) results, clinicopathologic characteristics, treatments, and outcomes in primary versus subsequent breast cancer (BC): Exploratory analysis of the Clalit Health Services (CHS) registry.
Journal of Clinical Oncology·2022
FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC)
Journal of Clinical Medicine·2022· 23 citedOpen Access
Abstract P1-08-14: Differences in Recurrence Score (RS) results between primary and second primary breast cancer (BC): Exploratory analysis of the Clalit Health Services (CHS) registry
Cancer Research·2022
page 1 of 5Next →

Frequent Co-authors

Addie Dvir(26), Nicky Liebermann(14), Salomon M. Stemmer(13), Nir Peled(12), Avital Bareket‐Samish(11), Noa Ben-Baruch(10), Maya Ilouze(9), Elizabeth Dudnik(9), Ayala Hubert(9), Vincent A. Miller(8), Shulamith Rizel(8), Baruch Brenner(8), Bella Nisenbaum(7), Georgeta Fried(7), Steven Shak(7), Ravit Geva(7), Ofer Purim(7), Doron Lipson(6), Jeffrey S. Ross(6), Ronen Brenner(6)